Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies

Cancer Research

Volumn 68, Issue 13, 2008, Pages 4998-5003

  Dechant, Michael ^a   Weisner, Wencke ^a   Berger, Sven ^a   Peipp, Matthias ^a   Beyer, Thomas ^a   Schneider Merck, Tanja ^a   Lammerts Van Bueren, Jeroen J ^b   Bleeker, Wim K ^b   Parren, Paul W H I ^b   Van De Winkel, Jan G J ^b   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4C; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; HB 8508; IMMUNOGLOBULIN G1 ANTIBODY; MATUZUMAB; PANITUMUMAB; UNCLASSIFIED DRUG; ZALUTUMUMAB; ANTIBODY; ANTINEOPLASTIC AGENT; COMPLEMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; BINDING AFFINITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL DESTRUCTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOLOGICAL MODEL; CELL CULTURE; CELL DEATH; CELL STRAIN CACO 2; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; EPITOPE MAPPING; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACO-2 CELLS; CELL DEATH; COMPLEMENT SYSTEM PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EPITOPE MAPPING; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 48549098958     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6226     Document Type: Article

References (23)

1. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1-13S.
2. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8.
3. Woof JM. Immunology. Tipping the scales toward more effective antibodies. Science 2005;310:1442-3.
4. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004;173:4699-707.
5. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-8.
6. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993;37:343-9.
7. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007;98:1275-80.
8. Sampson JH, Crotty LE, Lee S, et al. Unarmed, tumorspecific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci US A 2000;97:7503-8.
9. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
10. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol 2007;25:390-4.
11. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994;368:856-9.
12. Dechant M, Beyer T, Schneider-Merck T, et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 2007;179:2936-43.
13. Furuuchi K, Berezov A, Kumagai T, Greene MI. Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. J Immunol 2007;178:1021-9.
14. Bruggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-61.
15. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004;25:158-64.
16. Spiridon CI, Ghetie MA, Uhr J, et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo . Clin Cancer Res 2002;8:1720-30.
17. Macor P, Mezzanzanica D, Cossetti C, et al. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res 2006;66:3876-83.
18. Modjtahedi H, Eccles SA, Box G, Styles J, Dean CJ. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell Biophys 1993;22:129-46.
19. Friedman LM, Rinon A, Schechter B, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci US A 2005;102:1915-20.
20. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001;166:2571-5.
21. Xu YH, Richert N, Ito S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci US A 1984;81:7308-12.
22. Wiberg FC, Rasmussen SK, Frandsen TP, et al. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006;94:396-405.
23. Schmiedel J, Blaukat A, Li S, Knöchel T, Ferguson KM. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 2008;13:365-75.